ADMA — Stock Film
STOCK FILMSCENE 1/11ADMA · $9.84
Stock Expert AI presents
ADMA
ADMA Biologics, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
ADMA Biologics, Inc. A quick introduction.

On the stock market since 2013, it operates in the world of health and science. It has 685 employees. Now — the numbers.

on the stock market since 2013
685 employees
$3.6B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $29 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 29%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
97%ADMA BioManufacturing
ADMA BioManufacturing 97%Plasma Collection Centers 3%
97% of all revenue comes from a single line: ADMA BioManufacturing.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales are growing, year after year.

Average growth of 58% a year over the last 4 years. Red columns mark years that ended in a loss.

$80.9M
2021
$154.1M
2022
$258.2M
2023
$426.5M
2024
$510.2M
2025
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
97
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
71
strong

Clearly above the class average — a step short of the very top.

VALUATION
74
strong

Clearly above the class average — a step short of the very top.

GROWTH
81
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
28
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 5 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
Few are betting against it10/10
WEAK SPOTS
The stock has lost its spark0/10
Little set aside for the future2/10
Executives aren’t buying3/10
WORTH WATCHING

R&D Investment: Spending on future research is low.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 60% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
A fat but narrowing margin

The net profit margin is 29% — still a thick cushion, though costs have been eating into it lately.

2
THE BRIGHT SIDE · 2/3
Sales keep climbing

Over the last 3 years, sales grew about 49% a year on average.

3
THE BRIGHT SIDE · 3/3
Strong cash, light debt

There is $87.6M in the vault; even if every debt were paid off, $7.7M would remain.

1
THE RISKS · 1/3
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 28/100. For a turnaround signal, the stock first needs to close the gap with the market.

2
THE RISKS · 2/3
Little set aside for the future

The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.

3
THE RISKS · 3/3
Executives aren’t buying

No clear buy-side message is coming from the executive floor. Council score: 3/10.

FINALE · THE GRADE
A
0 / 100 · MoonshotScore

On our five-subject report card, ADMA sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: ADMA is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 22, 2026 · stockexpertai.com · Stock Film